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Abstract
Background: Human visceral leishmaniasis (VL), a potentially fatal disease, has emerged as an important opportunistic
condition in HIV infected patients. In immunocompromised patients, serological investigation is considered not an accurate
diagnostic method for VL diagnosis and molecular techniques seem especially promising.
Objective: This work is a comprehensive systematic review and meta-analysis to evaluate the accuracy of serologic and
molecular tests for VL diagnosis specifically in HIV-infected patients.
Methods: Two independent reviewers searched PubMed and LILACS databases. The quality of studies was assessed by
QUADAS score. Sensitivity and specificity were pooled separately and compared with overall accuracy measures: diagnostic
odds ratio (DOR) and symmetric summary receiver operating characteristic (sROC).
Results: Thirty three studies recruiting 1,489 patients were included. The following tests were evaluated: Immunofluo-
rescence Antibody Test (IFAT), Enzyme linked immunosorbent assay (ELISA), immunoblotting (Blot), direct agglutination test
(DAT) and polimerase chain reaction (PCR) in whole blood and bone marrow. Most studies were carried out in Europe.
Serological tests varied widely in performance, but with overall limited sensitivity. IFAT had poor sensitivity ranging from
11% to 82%. DOR (95% confidence interval) was higher for DAT 36.01 (9.95–130.29) and Blot 27.51 (9.27–81.66) than for IFAT
7.43 (3.08–1791) and ELISA 3.06 (0.71–13.10). PCR in whole blood had the highest DOR: 400.35 (58.47–2741.42). The
accuracy of PCR based on Q-point was 0.95; 95%CI 0.92–0.97, which means good overall performance.
Conclusion: Based mainly on evidence gained by infection with Leishmania infantum chagasi, serological tests should not
be used to rule out a diagnosis of VL among the HIV-infected, but a positive test at even low titers has diagnostic value
when combined with the clinical case definition. Considering the available evidence, tests based on DNA detection are
highly sensitive and may contribute to a diagnostic workup.
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Introduction
Leishmaniasis gained higher clinical importance in individuals
infected with HIV-1 (human immunodeficiency virus type-1) as an
opportunistic infection in areas where both infections are endemic.
In immunocompromised patients, the clinical course of the disease
is even less specific and can be masked by other associated
opportunistic infection [1]. Co-infected patients classically present
a chronic clinical course and high rate of treatment failure [2].
There is no doubt that the actual number of documented cases of
co-infection is underestimated due to the various problems in
recognition, diagnosis and reporting of either HIV-1 infection, or
leishmaniasis or both, in the setting of developing countries [3].
Parasitological diagnosis remains the gold standard in the
diagnosis of leishmaniasis mainly because of its high specificity [4].
Demonstration of Leishmania parasites in bone marrow aspirate or in
other biologicspecimens,either byvisualizationorculture,isalso the
most reliable diagnostic technique in the setting of HIV co-infection.
However, microscopic examination requires invasive procedures
and in vitro parasite isolation is difficult and time-consuming.
Antileishmanial antibodies have high diagnostic value in
immunocompetent patients [5,6] and a wide range of serological
methods varying in sensitivity and specificity are available for the
VL diagnosis. For immunosupressed individuals, serological inves-
tigation is considered not an accurate diagnostic method since a
large number of these patients do not harbor antibodies detectable
www.plosntds.org 1 May 2012 | Volume 6 | Issue 5 | e1665by standard techniques based on studies done in Europe [7–9] and
in Africa (6). Moreover, there is some doubt whether one se-
rological technique would be superior to the other for the VL
diagnosis among HIV-infected patients [8,10–12] and if there is
difference in tests performance among global regions.
Over the past 10 years, several molecular techniques targeting
various parasite genes have been developed for VL diagnosis. The
polymerase chain reaction (PCR) based method is the most
common molecular test successfully used and its use looks specially
promising in immunosupressed patients [13–16]. This technique
has emerged as a more rapid, sensitive, and specific than the
traditional diagnostic methods for VL diagnosis [15,17,18].
To our knowledge, antibody detection and molecular tests for
the VL diagnosis among HIV-infected patients has not been
systematically reviewed and synthesized. We therefore conducted
a systematic review to summarize the evidence on diagnostic
accuracy (sensitivity and specificity, likelihood ratio, diagnostic
odds ratio and Q point from summary ROC curve) of available
serological and PCR-based tests, according to the guidelines and
methods proposed for diagnostic systematic reviews and meta-
analysis [19,20].The aim of this study is to appraise the diagnostic
accuracy of serologic and molecular tests for detecting symptom-
atic visceral leishmaniasis in patients infected by HIV.
Materials and Methods
Literature Review
Selection was made independently by two reviewers (GFC and
MRS) and discrepancies were solved by consensus after discussion.
PubMed database search was performed using terms shown in
Figure 1. A similar search by using Boolean operators in LILACS
database was done.
The selected articles were read in full to confirm eligibility and
doubts or disagreements were solved by discussion with a third author
(AR). We searched both databases for articles published until 27, July
2011 that reported any available serologicormoleculartests for visceral
leishmaniasis diagnosis in HIV-infected individuals over 14 years with
symptomatic VL and diagnostic confirmation by examination by par-
asitological, serologic or molecular tests. No restrictions were made
with respect to study design (cross sectional or case control) or data
collection (prospective or retrospective). We obtained additional articles
by citation tracking of review articles and original articles.
We excluded studies reporting other immune-depressing con-
ditions when co-infected patients with HIV were not identified,
series presenting 10 or less patients tested by the index test, review
of series of cases and studies where separated results for each
serologic test were not presented.
Data Extraction
Data were extracted by one reviewer directly from the full
length articles to structured tables containing all the descriptive
Author Summary
Human visceral leishmaniasis (VL), a potentially fatal
disease, has emerged as an important opportunistic
condition in HIV infected patients. In immunocompro-
mised patients, serological investigation is considered not
an accurate diagnostic method for VL diagnosis and
molecular techniques seem especially promising. Demon-
stration of Leishmania parasites in bone marrow aspirate
or in other biologic specimen, either by visualization or
culture, remains the most reliable diagnostic technique in
the setting of HIV co-infection. However, these tests are
difficult to perform in rural areas and some of them are
invasive and carry a risk of complication. This work is a
systematic review to evaluate the accuracy of serologic
and molecular tests for VL diagnosis in HIV-infected
patients. Two reviewers searched the literature, evaluating
quality of studies and comparing performance of diagnos-
tic tests. Thirty three studies were included. Most studies
were carried out in Europe. Serological tests varied in
performance, but with overall limited sensitivity. Based on
the evidence, serological tests should not be used to rule
out a diagnosis of VL among HIV-patients, but a positive
test at even low titers has diagnostic value when
combined with the clinical case definition. Tests based
on DNA detection are highly sensitive and may contribute
to a diagnostic workup.
Figure 1. Terms used in PubMed search.
doi:10.1371/journal.pntd.0001665.g001
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      variables and test results. A second researcher independently
double checked the extraction of primary data from every study.
Discrepancies were resolved by discussion. The following infor-
mation was extracted: country in which the study was carried out,
diagnostic methods applied, reference test used, characteristics of
the participants, study design and quality, sample size, manufac-
turers and antigens used and titles for defining test positivity and
outcome data (sensitivity and specificity were calculated when
available data were presented). In many articles the numbers of
true positive, false negative, true negative, and false positive
observations were available. If not, we derived the numbers from
the marginal totals and the reported sensitivity and specificity.
The number and type of participants were recorded and
categorized as confirmed cases (HIV-infected individuals with VL)
or controls (HIV-infected individuals without VL). Although some
authors compared performance of tests in several different groups
without VL, we selected only two possibilities of comparison group
(control participants): 1- HIV-infected patients with the same
clinical syndrome as confirmed cases with visceral leishmaniasis
ruled out 2- HIV-infected patients without signs or symptoms of
leishmaniasis.
Assessment of Study Quality
We assessed the quality of studies using the Quality Assessment
of Studies of Diagnostic Accuracy Approach-QUADAS [21],
which contains 14 items specifically developed to assess the quality
of primary studies of diagnostic tests.
Data Synthesis and Statistical Analysis
The statistical analysis was based on the following steps: (1)
qualitative description of findings; (2) search for the presence of
publication bias, heterogeneity and threshold effect; (3) exploring
possible explanations for heterogeneity; (4) statistical pooling of
sensitivity, specificity and two global measures of accuracy of tests:
diagnostic odds ratio (DOR) and symmetric summary receiver
operating characteristic (sROC).
Publication bias was evaluated through Egger’s test [22] by
using Comprehensive Meta Analysis SoftwareH v. 2.2.048 (CMA).
Publication bias has been defined as the tendency on the part of
investigators to submit, or the reviewers and editors, to accept
manuscripts based on the direction or strength of the study
findings. This definition concentrates on the fact that the strongest
and most positive studies are most likely to be published.
Heterogeneity was explored with I
2 estimate from Cochran Q
(the most commonly used heterogeneity statistic) according to the
formula: I
2=100%6(Cochran Q –degrees of freedom)/Cochran Q
[23]. One must understand heterogeneity as a greater variation of
sensitivity, specificity or DOR between the included studies than is
compatible with the play of chance. This statistical heterogeneity
should represent other sources of differences such as clinical, tests
or research design characteristics.
In nearly all situations sensitivity and specificity are not
independent, what is called threshold effect. For this reason, sen-
sitivity and specificity are considered inappropriate for meta-
analyses, as they do not behave independently when they are
pooled from various primary studies to generate separate averages
[24]. The threshold effect may be caused by explicit differences in
either positive cut-off definitions or implicit population and
methodological differences among studies [19]. A robust approach
to combining data and estimating the underlying relationship
between sensitivity and specificity is the construction of a sROC
curve. Methods that involve pooling sensitivities and specific-
ities from individual studies, or combining positive and negative
likelihood ratios fail to account for the paired nature of the
parameters, and should generally be avoided [25].
According to Centre for Reviews and Dissemination (CRD)
guidance for undertaking systematic reviews ‘‘where only one
parameter (e.g. sensitivity, but not specificity) is presented, simple
pooling of proportions is the only option. Assessment of single
parameters is usually inappropriate, but is sometimes used when
there is a specific clinical reason why only one parameter should
be the focus of interest’’ [26]. Thus, given the small number of
available studies and the paucity of data on the performance of the
test in control populations (HIV-infected patients without VL),
besides global analysis including few studies presented both
sensitivity and specificity, we decided to pool sensitivity and
specificity separately of all studies in order to compare results and
check if both approaches would reach the same or different
conclusions. Our intention was to discuss the methodological
possibilities and assess the reliability of our results. Statistical
analyses were carried out with the open source statistical language
and environment R 2.0.1 [27].
Tocalculatesensitivityandspecificityvaluesforthetests,wecross-
tabulated each result against the reference standard. Whenever
possible,weextractedrawdatafromprimarystudiestofillinthefour
cell values of a diagnostic 262 table: true positives, false positives,
true negatives, and false negatives. When studies did not provide
confidence intervals for sensitivity or specificity, we estimated them
from the reported 262 table [28] using Wilson score method [29].
When available, study results were pooled using a DerSimonian
Laird method (random effects meta-analysis model) from Meta-
DiscH 1.4 analysis software [30]. It was used to obtain pooled
results of sensitivities, specificities, positive (PLR) and negative
likelihood ratio (NLR). The likelihood ratio for a positive result is
sensitivity divided by 1- specificity and tells how much the odds of
the disease increase when a test is positive. A PLR can be used to
assess the impact on diagnosis of a positive test result for an
individual. The likelihood ratio for a negative result is 1- sensitivity
divided by specificity and tells how much the odds of the disease
decrease when a test is negative. Pooled likelihood ratio is useful
since it can be used directly in the Bayes rule: Post-test odds=pre-
test odds6LR. In addition, true positive rates (TPR=sensitivity)
and false positive rates (FPR=1-specificity) were summarized
using a sROC curve [32]. The Q-point (point on curve where
sensitivity equals specificity) obtained from the sROC curve was
used as a measure of global accuracy [25]. Also used to compare
overall accuracy among tests, diagnostic odds ratio (DOR) with
fixed effects model were obtained from CMAH software. The
DOR of a test is the ratio of PLR divided by NLR. Pooling
sensitivity and specificity separately assumes that the diagnostic
threshold is the same in each study. Pooling DORs relaxes this
assumption by assuming that the studies relate to the same sROC
curve. The DOR has been put forward as a useful single indicator
of test performance, which indicates the strength of the association
between test results in disease [31]. It is difficult to be clinically
interpreted, but useful from the statistical point of view in the
assessment of the overall test accuracy in meta-analysis [19,31,33].
Results
From the literature searches, we identified 432 primary citations
from PubMed and 132 from LILACS. Seven additional articles
(references from primary articles) were also found. Publication
year ranged from 1989 to 2009. Study selection flow is shown in
Figure 2.
All 132 citations from LILACS and 370 from PubMed were
excluded by the reading of titles and/or abstracts. Thirty three
Leishmaniasis and HIV: Diagnostic Tools
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reported less than 10 patients tested, four were a review or
correspondence, fifteen studies did not report tests results or the
immunosupressed patients could not be identified, one was a
prevalence study to detect the presence of asymptomatic carriers
in a given population and seven studies were excluded because
they included cases published elsewhere. Thirty three studies
recruiting 1489 patients were included. A total of six different
serological tests were found: direct agglutination test (DAT),
indirect fluorescent antibody test (IFAT), Enzyme linked immu-
nosorbent assay (ELISA), Immunoblotting (Blot), rapid K39-based
immunochromatographic test and Haemagglutination (HA). We
found only two studies [34,35] addressing the performance of two
different commercial counter-immunoeletrophoresis tests (com-
monly referred to as rapid diagnostic tests) among HIV-infected
patients. Only one from them stated sensitivity and specificity. No
studies involved individuals younger than 15 years old. Table S1
summarizes the characteristics of the 33 studies.
The study quality analysis as assessed by QUADAS tool showed
that 24 out of 33 studies (73%) met more than seven criteria (Table
S2). Regarding study design and execution, fifteen studies were
identified as retrospective or a clinical database analysis (set of data
systematically gathered on all patients even though no specific
analysis was prospectively planned). Sixteen reports were truly
prospective and two had transversal design. In addition, a minority
of them (8 studies) reported consecutive patient inclusion as the
method of participant selection. Only two studies [8,36] reported
at least single blinded interpretation of index test and reference
standard results. For most studies information about the condition
of the specimens (frozen or fresh) was unclear or not reported.
Figure 2. Study selection process.
doi:10.1371/journal.pntd.0001665.g002
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done with stored sera.
The reference standard for all studies was a positive result on
direct microscopically examination or culture of blood or bone
marrow aspirate, and in few cases, from another sample tissue. In
one study diagnosis could also be confirmed by serology [16] or
detection of parasites by polymerase chain reaction [39] associated
with clinical signs. In these two studies the index test did form part
of the reference standard. In 7 of 13 studies evaluating control
patients, the entire study population was investigated using the
identical reference standard (complete verification). In other five
studies the reference standard for VL patients and control par-
ticipants differed (e.g., parasitological tests for VL patients and
serological tests for control participants (differential verification)
and one study did not report the test used for control verification
[35]. Five studies had as control group HIV-infected individuals
without clinical signs of disease.
Most studies (28/33) included less than 100 patients and only 14
out 33 studies (42%) provided detailed clinical characterization of
the studied population. The specific antigen composition was
described in 14 out of 21 studies (62%) evaluating IFAT tests. Six
from these studies used a commercial test based on axenic cultures
of L. infantum; two other studies used commercial tests based on
L. tropica [40] and L. donovani [41] culture. Seven studies used
antigen prepared from whole promastigotes of the World Health
Organization strain.
Published experience with ELISA is very scarce: there are six
studies. Two studies searched antibodies to recombinant (r)
antigen K39 while other two [18,42] used antigen extracted from
promastigotas strain of L. infantum. The other two studies [43,44]
assessing ELISA performance did not report the antigen used.
Regarding immunoblotting, most authors considered the
criterion for positivity the detection of antibodies to the 14- kD
antigens with or without antibodies to other low molecular weight
bands [18,43–46]. Santos-Gomes and others [10] assumed as
positive result the presence of any band since the sera from the
control groups did not recognize any Leishmania antigen. Medrano
et al. [8] considered an immunoblotting reactive when one or
more bands of any molecular weight detected were present in at
least two patients with VL, but not in the negative control sera
from the no endemic area.
Details of the PCR techniques used are summarized in Table
S1. Whole blood was used in all but four studies evaluated also
PCR use in bone marrow samples [16,39,47,48]. Several
variations in the PCR technique were used: small subunit
ribosomal RNA (ssu-RNA) from L. infantum [16,39,48–50], ssu-
rRNA from L. donovani [36], repetitive nuclear sequence (140 bp)
from L. infantum [18] and nested-PCR (100 bp) from L. infantum.
Only 13 studies evaluating 5 tests [7,8,10,12,35,36,44,46,50–54]
showed results of both sensitivity and specificity, the requirement
to testing threshold effect presence. It should be noted however
that for samples with less than 10 studies is not possible to state at
significance level of 5% there is not threshold effect for studies in
which the correlation result was negative.
Corresponding sROC plots of the studies and estimated DOR
(95% confidence interval) of tests are shown in Figure 3. For DOR
analysis, the global accuracy of DAT 36.01 (9.95–130.29, I
2=0)
and Blot 27.51 (9.27–81.66, I
2=56) was comparable and higher
than IFAT 7.43 (3.08–1791, I
2=11) and ELISA 3.06 (0.71–13.10,
I
2=87), in spite of wide confidence intervals. PCR in whole blood
had the highest DOR: 400.35 (58.47–2741.42, I
2=0). Pooled
NLR for IFAT 0.7 (0.5–1.1) is higher than Blot 0.21 (0.12–0.42).
Egger’s test 2-sided p value was larger than 0.05, suggesting
absence of publication bias for all tests.
Figures 4 show the results of individual and combined sensitivity
and sensitivity estimates for the tests including all studies. On the
whole, sensitivity varied widely among studies of a given type of
test and in studies across different types of tests. There is high
heterogeneity across studies for most tests (Table S3 and Table
S4). Although we used random effects model to summarize data,
a point estimate of separated sensitivity or specificity must be
evaluated carefully. IFAT was the test most frequently evaluated in
the review (21 studies) with sensitivity values ranged from 11% to
82%. Sensitivity was less than 50% in ten out 21 (48%) studies;
specificity value ranged from 79% to 100%, with specificity .90%
in three out of four (75%) studies. The estimated sensitivity for the
IFAT using random effects model was 51% (95% confidence
interval 43% to 58%). Three studies [8,40,53] had even lower
sensitivity (11, 14 and 22%). Although all three had used as cutoff
1:80, we carried out separate analyses in subgroups stratified by
cut-off value, sample size, study design, geographical region, and
type of controls and we did not find any significant difference
except for QUADAS score, which showed an inverse association
with sensitivity (data not shown). It was not possible to assess the
heterogeneity between studies according to geographic region due
to the small number of studies outside Europe.
The estimated sensitivities using random effects model and their
respective 95% confidence intervals for the other tests were: Blot
84% (75% to 91%), DAT 81% (61% to 95%), ELISA 66% (40%
to 88%), PCR in whole blood 92% (83% to 98%) and PCR in
Figure 3. Tests performance summary. Footnote: Immunofluorescence antibody test (IFAT), Enzyme linked immunosorbent assay (ELISA),
Immunoblotting (BLOT), direct agglutination test (DAT) and polymerase chain reaction (PCR) in whole blood, standard deviation (SD), 95% confidence
interval (95% CI), *standard error (SE). * SE is a measure of precision and it is not a measure of confidence interval, which is shown in sROC plot, except
for ELISA.
doi:10.1371/journal.pntd.0001665.g003
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options: fixed and random effects model. When both results are similar with low heterogeneity, both can be used. When they are different, we prefer
results from random effects model, which gives wide and conservative confidence interval for heterogeneous results.
doi:10.1371/journal.pntd.0001665.g004
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found significant heterogeneity for the same test across several
studies but high overall pooled specificity for all of them. The
estimated specificity using random effects model and their
respective confidence intervals for following tests were: Blot 82%
(65% to 94%), ELISA 90% (77% to 98%), IFAT 93% (81% to
99%), DAT 90% (66% to 100%), PCR in whole blood 96% (80 to
100%).
Figure 5 shows performance for PCR in peripheral blood
through a sROC curve. The accuracy of PCR based on Q-point
was 0.95; 95%CI 0.92–0.97, which means good overall perfor-
mance.
Discussion
Our data allow some conclusions based on available evidence,
which essentially reflect the European experience with serological
and molecular diagnosis of VL among HIV-infected: (1) the
available evidence is limited and there is great variability among
the studies; (2) the accuracy of molecular methods is greater than
the serological methods; (3) DAT and Blot have better global
accuracy among serological tests; (4) although specificity was
generally high for all serological tests, there is unexpectedly high
variation in specificity among studies evaluating the same test; (5)
serological tests vary widely in performance, but with overall
limited sensitivity in HIV infected patients. It is very important to
note that high concentration of cases of Leishmania-HIV co-
infection is found in Africa and Asia continents and it is possible
that these findings can not be extrapolated to these populations.
However, this is a critical summary of the evidence currently
available.
Several indicators of diagnostic performance have been pro-
posed, such as sensitivity and specificity. Using paired indicators can
be a disadvantage incomparingtheperformanceofcompetingtests,
especially if one test does not outperform the other on both
indicators. The DOR is a single indicator of diagnostic perfor-
mance;itfacilitates formalmeta-analysisofstudies ondiagnostic test
performance [31]. Based on DOR, we observed superiority of PCR
above serologic methods. Among serologic tests, based on DOR, we
observed that Blot and DAT are superior to ELISA and IFAT.
Pooled NLR (95% confidence interval) for IFAT 0.74 (0.51–1.09) is
higher than Blot 0.21 (0.12–0.42), confirming that especially IFAT
is not an appropriate test to exclude diagnosis, since its negative
predictive value will be low. Blot and DAT had better sensitivities
than the other serologic tests evaluated.
The sensitivity values of each study are consistent with the values
of the studies combined and we can affirm that IFAT sensitivity is
very limited and heterogeneous. An explanation for this heteroge-
neity is the quality of the studies, which is suggested by the indirect
comparison between QUADAS score and sensitivity of IFAT.
Among the studies assessing IFAT, one study [37] is distinguished
by exceptionally high sensitivity displayed (81%). According to this
author, the performance obtained using IFAT prepared with
reference L. infantum strain from WHO (MHOM/TN/80/IPT1)
was significantly better than prior local experience with commercial
IFAT kits. This may mean that variables related to the preparation
of the antigen and regional differences in prevalence and strain of
Leishmania, in addition to the characteristics of the tested popula-
tions, have a greater impact on test performance [55].
Pooled specificity is high among all serologic tests. Nevertheless,
we found great variability in the results for the same test across
different studies. Especially for one DAT study [54] and one Blot
Figure 5. sROC curve for PCR in peripheral whole blood.
doi:10.1371/journal.pntd.0001665.g005
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high sensitivities, suggesting threshold effect. The sensitivity and
specificity of such diagnostic methods depend on the type, source,
and purity of antigen employed, as some of the Leishmania antigens
have common cross-reactive epitopes shared with other microor-
ganisms such Trypanosome brucei subspecies, Trypanosome cruzi and
M. tuberculosis [6]. In addition, the type of controls significantly
influenced the estimates for specificity. Studies including healthy
controls tend to show higher specificity than those recruiting
patients with clinically suspected disease consecutively and
prospectively in a representative clinical setting.
DAT based on whole promastigotes of L. donovani or L. infantum
are tests used widely for the diagnosis of VL. However, the major
disadvantage of this technique is the limited production facility of
quality controlled antigen. A recent meta-analysis of the DAT
performance among immunocompetent individuals showed sensi-
tivity and specificity estimates (and 95% confidence interval)
of 94.8% (92.7% to 96.4%) and 97.1% (93.9% to 98.7%),
respectively [56]. Despite lower performance in HIV-infected
patients than in immuncompentents, DAT (and Blot) proved to be
the most effective serological technique in those immunosupressed
by HIV infection. However, only four studies assessing DAT with
sensitivities and specificities, none from Latin-America and only
one from Europe could be included. One [7] out of these four
studies exhibited discrepant and very low sensitivity, despite use of
1:400 cut-off. Specifically this study was performed in Italy (the
others were conducted in India and Ethiopia) and DAT was
carried out using promastigotes of L donovani sensu latu. This may
represent the relevance of the prevalent strain in the performance
of a test prepared from promastigotes (local antigen specificity) or
the difference in immune response induced by more or less
anthroponotic strains of Leishmania.
Some heterogeneity in sensitivity of the tests seemed to be
related to the geographical location of the study. Differences in test
performance between regions is attributable basically to parasite
diversity [57], but it can also be related to differences in antibody
concentrations which may in turn be linked to different age
patterns, immune and/or nutritional status of patient. In this
review, it was not possible to evaluate the test’s performances in
various endemic regions of world. All included studies assessing
IFAT, Blot and ELISA were performed in Europe. Data on DAT
essentially reflect the response in Ethiopia and Italy, with only one
study performed in India (few patients). No study from the
Americas was found. Regarding rK39 dipstick test, the only two
studies [34,35] found, one carried out in India and one in
Ethiopia, exhibited different sensitivities. Similarly, among non
HIV-infected patients results between global regions were
substantially different. There is data showing the low sensitivity
of rK39 based dipsticks in Sudan [58–60] and better results in
studies from South Asia [56].
Serological tests have an already recognized low sensitivity for
the diagnosis of VL among HIV-patients [61]. Gradoni et al. [37]
suggested that the serological response could be related to the
sequence of temporal acquisition of the infectious agents.
Seropositivity would represent a reactivation of latent infection
before the immune depression caused by the viral infection
(asymptomatic carriers), while seronegativity would result from
primary Leishmania infections after viral infection. However, the
severe dysfunction of T and B lymphocytes in HIV-infected
individuals, an alteration in antigen presentation by macrophages
or in T and B lymphocyte cooperation would explain the decrease
in specific antibody production, as occurs for other infections [1].
It is also necessary to note that most serological studies from
Europe date from the early stages of the HIV epidemic, while the
PCR studies were usually done when HAART was available.
Possibly, different types of populations (more advanced HIV
disease in the earlier studies) were included.
Standard techniques for assessing diagnostic tests assume that a
definitive reference test is available, that is, that the reference test
used is as close to 100% accurate as can be. However, it may be
either that the available test is far from perfect or that such a test
simply does not exist [23]. The presence of Leishmania parasites
may only be demonstrated incontrovertibly by the microscopically
examination of smears or the culture of blood or biopsy samples.
Microscopical examination of spleen aspirates is sensitive and
specific but requires expertise to carry out the aspiration safely and
to read the slides accurately. Examination of bone marrow or
lymph node aspirates is equally specific but less sensitive [62].
Parasite load is quite heavy in VL-HIV co-infected patients and
the presence of Leishmania amastigotes in the bone marrow can
often be demonstrated. However there are well-described instanc-
es in the literature where amastigotes were not demonstrable in
bone marrow, though they were found at unexpected locations like
the stomach, the colon, or the lungs [5]. The majority (31/33,
94%) of studies used exclusively microscopic determination of
parasites as the reference standard. Although direct and culture
are considered the definitive diagnosis, parasitological methods
does not detect all cases of VL; therefore, some degree of mis-
classification of disease for study participants was possible.
In the case of molecular tests, previous studies suggest their
greater sensitivity compared to the classical parasitological
methods [13]. As a result, some authors used a combination of
several laboratory tests and clinical manifestations as reference
test. Incorporation bias occurs where the experimental test is used
as part of the reference strategy, that is, the experimental test and
reference tests are not independent, leading to overestimation of
both sensitivity and specificity. Based on prevalence studies, the
proportion of individuals identified as asymptomatic carriers of
Leishmania by PCR methods is not negligible [63]. None of the
studies testing PCR included here assessed the proportion of
asymptomatic patients co-infected with Leishmania and HIV. An
important point to notice is that molecular tests are still expensive
and require sophisticated laboratory setting; these features
represent real obstacles to their implementation in the regions
with the highest absolute numbers of HIV-VL coinfection cases
(East-Africa and India). This performance data can be used to
guide priority setting for field trials and/or procurement decisions.
The final decision on product selection needs to be taken in a
rational way, considering not only the minimal performance limits,
but also the global endemic region, patient characteristics, ex-
perience of the intended users, climate and costs.
During the past few years, numerous studies have investigated
Leishmania antigen expressions at the level of specific antibody
recognition. Using immunoblotting techniques, several L. infantum
antigens that appeared promising for establishing an immunodi-
agnosis of VL in nonimmunocompromised hosts have been
identified [8]: 70–72 kD, 94 kD, 14–16 kD, 39 kD, 24 and 32 kD,
but a clear pattern of specific immune response to parasite an-
tigens during the active course of the disease has not been yet
defined. Mary and others [64] in a series of 11 AIDS cases found a
similar pattern of reactivity between HIV and non-HIV patients
with VL that differed only in the variable presence of a 14-kD
band in the former group. The 16-kD antigenic component was
considered as the more sensitive and specific diagnostic band.
Rosenthal and others [43] in another study carried out in the same
endemic area (southern France) reported the presence of bands of
molecular mass 14 kD and 16 kD in 15 of the 18 evaluated cases.
In Medrano et al [8] study, immunoblots were found to be reactive
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groups of parasite antigens (14 kD, 42–43 kD, 57 kD, 76 kD, and
94 kD) appear to have potential use for diagnosis although the
pattern of reactivity observed during the acute VL disease was very
variable. Among the nine studies evaluating immunoblotting,
performance described by Piarroux and colleagues [18] is dis-
tinguished by low sensitivity (63%). In this study, unlike the others, a
more sensitive reference test was used and included visualization of
Leishmania in any specimen collected at the same period, besides in
bone marrow aspirate. However, strict comparisons between results
reported in the literature are rather difficult because of the
variability in the techniques and the use of different strains and
antigens. Considering the high variability of the immunoblotting
patterns, it seems that a combination of several antigens should be
used, as has been previously suggested [8,65].
Moreover, different settings (e.g., difference in Leishmania
prevalence may have accounted for some variation in test per-
formance. It is often assumed that indices of test accuracy such as
sensitivity and specificity are fixed (for a given threshold). But they
can vary as a function of prevalence [66,67]. When spectrum bias
is present, either sensitivity or specificity would be expected to
change. Sensitivity would be expected to increase where test results
become more extreme in patients with the most severe disease (i.e.
more likely to test positive). Specificity is affected by a variety of
alternative diagnosis in those without the target disorder that could
cause false positive results. The range of such diagnosis is likely to
be wider in studies that have a lower prevalence of the target
disorder [23]. Another problem concerned to limited information
on clinical status and disease severity in the populations tested.
Differing criteria for patient selection, age, duration of illness and
severity of HIV-disease of the study populations may have
introduced significant variability in findings among studies
(selection bias).
There are also limitations in studies methods. The differences in
PCR methods included the nature of the samples (whole blood or
bone marrow aspirate), volume tested, DNA extraction proce-
dures, choice of target gene, detection of PCR products and the
use of appropriate controls. All of these factors have been reported
as likely causes of heterogeneity and they were all present in the
studies included. Interpretation of many diagnostic tests involves
some degree of subjective interpretation. Only two of the studies
(6%) reported blinded interpretation of the results of the index test
and the reference standard. Lack of blinding may have resulted in
an overestimation of the sensitivity of the index test result. In
additional, the condition of specimens may also have affected the
sensitivity results. The vast majority (91%) of studies did not report
if frozen or fresh sera were used. In 5 from 13 studies (38.5%),
different diagnostic tests were performed in VL patients and
control participants: parasitological tests for patients and serolog-
ical test for control participants [verification bias]. In one study
[35] the information about the test used to rule out VL was not
reported.
This comprehensive review is mainly limited by quality of
available studies. We believe that pooled measures from different
studies help to appraise global accuracy. Nevertheless, its validity
remains on scarce evidence that may change as larger well designed
studies are done. No large prospective clinical studies evaluating
either serological or molecular tests have been reported. In addition,
available data are not representative of all endemic regions. Data
about HA, rapid K39-based immunochromatographic and PCR
test in bone marrow aspirate could not be analyzed due to the
paucity of studies. The same way, there were too few studies to
explore by subgroup analysis or metaregressing whether the
diagnostic yield of the methods was different among subgroups
(i.e., control characteristics, sample size, study design and quality)
or whether the different techniques influenced the results. The
heterogeneity among studies evaluating the same method makes
pooled sensitivity and specificity measures less reliable. The
strategies of pooling sensitivity and specificity or using global
accuracy measures like DOR and sROC are subject to different
kind of bias. Including studies with more quality, although in low
number, reduce the bias of methodological flaws changing results.
Including more studies pooling separately sensitivity and specificity
reduce the bias of selecting low number of studies. In spite of these
different biases, by using both methods we found very similar results
confirming the consistency of these observations.
Conclusions
The results of this evaluation confirm the low sensitivity of the
serologic tests for VL diagnosis in HIV-infected patients. Except
for DAT, currently available evidence about performance of
serological tests refers to Leishmania infantum chagasi, the etiologi-
cal agent of visceral leishmaniasis in the Americas and in the
Mediterranean basin. Our results indicated superiority of Blot over
IFAT and ELISA. DAT seems to be better than IFAT and ELISA,
like Blot, but its performance may be influenced by difference in
geographic region, meaning different Leishmania species. As the
performance of DAT and Blot is comparable, the choice should be
made on the basis of other criteria such as region, cost, feasibility,
and sustainability. Given these findings, we express concern that
IFAT remains the most frequently serological test used for VL
investigation in South America, even among HIV-infected. At this
time, there is no evidence to support recommendations on
serologic or molecular diagnosis of VL in patients infected with
HIV and living in East Africa or Southeast Asia. The development
of the rK39 dipstick has brought a major improvement in the
diagnosis of VL in non HIV-infected patients in the field.
Nevertheless, the paucity of data about the rK39 dipstick in
HIV-infected patients underscores the need for more research
before it being integrated in a diagnostic algorithm.
In spike of lack of homogeneity of the PCR methods used,
available evidence suggests that, at this point in time, published
data on molecular tests produce consistently good estimates of
accuracy. Its main weaknesses are the lack of standardization
for the technique. We must also point out that the meaning of
Leishmania infection detected by PCR in asymptomatic individuals
is not yet defined. This fact might raise questions about possible
false-positive results. In addition, alternative methods must be
developed to solve the ‘‘gold standard problem’’. A promising
strategy is Bayesian latent class models [68].
More studies are needed to compare tests for VL diagnosis in
different regions. This highlights the need to implement a
diagnostic algorithm as appropriate for each global endemic area.
The design of diagnostic studies must follow the STARD initiative
[69] as a way to minimize bias.
In conclusion, based on the available evidence, serology should
not be used to rule out a diagnosis of VL among HIV-infected
patients. An additional molecular or parasitological test may be
necessary if results of serological tests are negative. A positive
serological test at even low titers has diagnostic value when
combined with the clinical case definition. In its turn, tests based
on PCR are highly sensitive and should contribute to the
diagnosis, especially in areas of low endemicity.
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